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Objectives: The aim of this study was to establish baseline, pre-progression and 
post-progression health state utilities for nivolumab (NIVO) and dacarbazine (DTIC) 
for use in the economic evaluation of NIVO versus other interventions in unresect-
able stage 3 or stage 4 melanoma. MethOds: Utility data were collected during a 
phase III clinical trial study every 6 weeks via the EQ-5D-3L instrument and ques-
tionnaires scored using Australian specific weights within Microsoft Excel. Utility 
valuations and associated patient and disease data were exported to STATA 11.2. 
Descriptive statistics were generated, stratified by treatment, study epoch (screen-
ing; non-screening) and by progressive disease status. Results: Two hundred and 
one and 208 patients were randomized to NIVO and DTIC respectively. Mean utili-
ties for NIVO and DTIC respectively were: 0.78 (95% CI: 0.75,0.81) and 0.71 (95% CI: 
0.67,0.75) at baseline; 0.84 (95% CI: 0.83,0.85) and 0.78 (95% CI: 0.76,0.81) prior to 
the development of progressive disease; and 0.83 (95% CI: 0.80,0.86) and 0.70 (95% 
CI: 0.66,0.74) following development of progressive disease. For those randomised 
to NIVO, development of progressive disease per RECIST v1.1 criteria did not sig-
nificantly impact on utility (mean change= 0.01, p= 0.4618). By contrast, for those 
randomised to DTIC, development of progressive disease per RECIST v1.1 criteria did 
significantly impact utility (mean change= 0.08, p= 0.0005). cOnclusiOns: These 
results provide Australian specific utility valuations by health state to inform the 
economic evaluation of NIVO versus other interventions in unresectable stage 3 or 
stage 4 melanoma. Notably, for those receiving NIVO, the development of progressive 
disease per RECIST v1.1 criteria did not have a significant impact on mean utility, 
suggesting the benefits of NIVO on HRQoL persist beyond traditional measures of 
disease progression, in contrast to DTIC which exhibits the expected reduction in 
utility following development of progressive disease
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Objectives: The standardized incidence of women breast cancer (BC) in Slovakia 
is 51,6/100 000 and has growing trend. There were diagnosed 2423 new cases in 2012 
and 2639 new cases BC in Slovakia. BC has a great impact on quality of life (QoL). 
The objective of this paper was to find out the level of QoL in patients with BC in 
Slovakia. MethOds: The primary method used for the analysis of QoL was the 
combined questionnaire consisting of 5 parts: A. Demography (9 items), B. Clinical 
part (B1+B2, 17 items), C. Quality fo life with dominant numeric scale (13 items), D. 
Socio-economic part (9 items), E. EQ-5D. There were 112 patients in the examined 
group from the 150 asked to fill the questionnaire. Results: Present level of QoL 
was identified as 6,11 on the scale from 0 to 10, while in the time of the BC diagnosis 
it was 4,42. QoL was 8.22 in the time without BC and 8,73 in the total optimal state 
of health. Comparative to the QoL was examined the ability to work (AW) and so on 
the scale from 0 to 10. Present level of AW was identified as 5,40, while in the time of 
the BC diagnosis it was 4,44. AW was 8.41 in the time without BC and 9,00 in the total 
optimal state of health. The impact of treatment on QoL was 5,38 and the disease 
had impact 6,10 on family QoL. Disability was 77,35 days vs 16,45 opposite to disabili-
ties days from other reasons. The average income was 379,58 € and the willingness 
to pay for 1 month of full health was in average 132 € per months. cOnclusiOns: 
The disease had a significant impact on patients´s QoL . The treatment of BC had a 
significant impact on increasing QoL of patients.
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Objectives: The standardized incidence of kidney cancer (KC) in Slovakia was 
14,6/100 000 in men and 7,0/100 000 in women and has growing trend. There were 
diagnosed more than 800 new cases in 2013 of KC in Slovakia. The objective of this 
paper was to find out the level of QoL in patients with KC in Slovakia. MethOds: 
The primary method used for the analysis of QoL was the combined questionnaire 
consisting of 6 parts: A. Demography (9 items), B. Clinical part (B1+B2, 17 items), C. 
Quality fo life with dominant numeric scale (13 items), D. Socio-economic part (9 
items), E. EQ-5D (5 items), F. Symptoms of disease (9 items). There were 79 patients 
in the examined group from the110 asked to fill the questionnaire. All patients 
were treated by surgery. Results: Present level of QoL was identified as 6,32 on the 
scale from 0 to 10 (0- the worst,10 -thebest), while in the time of the KC diagnosis it 
was 5,15. QoL was 7,86 in the time without BC and 8,82 in the total optimal state of 
health. Comparative to the QoL was examined the ability to work (AW), too. Present 
level of AW was identified as 6,02, while in the time of the BC diagnosis it was 5,44. 
AW was 8.25 in the time without KC and 9,06 in the total optimal state of health. 
The impact of treatment on QoL was 6,34 and the disease had impact 5,94 on family 
QoL. The average income was 456 € and the willingness to pay for 1 month was in 
average 270 € per months to be complete healthy. cOnclusiOns: The disease had 
a significant impact on patients´s QoL nad patient´s family QoL, too. The treatment 
of BC had a significant impact on increasing QoL of patients.
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Objectives: Willingness-to-pay techniques are increasingly being applied in eco-
nomic evaluation, as a means of assessing the value of new health care technologies. 
The objective of the present study was to assess the willingness to pay for Human 
Papillomavirus vaccination and factors influencing the willingness to pay among 
health professional students as health professionals play a vital role in human pap-
invasive BC (MIBC), which is invasive and requires lifetime urinary diversion, was most 
commonly studied. In contrast, there is minimal literature on HRQoL of patients with 
advanced/metastatic urothelial BC and non-muscle invasive BC (NMIBC). Although 
longitudinal studies have been conducted in both MIBC and NMIBC, the interpretation 
of the results is hampered by study design issues (such as lack of baseline HRQoL data, 
insufficient follow-up duration, infrequent HRQoL assessment, and/or small sample 
sizes) and inconsistency in HRQoL instrument. cOnclusiOns: While there is a sub-
stantial body of literature describing the impact of BC on HRQoL, particularly MIBC, 
methodological rigor is lacking, limiting interpretation and full assessment of the 
impact of BC by disease stage and treatment. Further, HRQoL assessment in NMIBC 
and advanced/metastatic disease is rare and warrants additional research effort.
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Objectives: As new interventions and treatment decision aids for prostate cancer 
(PC) become available, health economic analyses will be required to evaluate their 
impact on health authorities and the burden of PC. An important aspect of this is 
understanding the quality of life (QoL) impact of PC, its comorbidities and treat-
ments. MethOds: A structured literature review was undertaken, with searches 
conducted in PubMed, EMBASE, and the Cochrane Library. Literature review was con-
centrated on publications with a major focus on “Prostatic Neoplasms” or containing 
the term “Prostate Cancer”. Secondary search criteria restricted results to contain 
information on quality of life, health state utilities, or recognized QOL question-
naires. To ensure that recent estimates were evaluated, literature was restricted to 
those published on or after January 1, 2009. Abstract screening was performed by a 
single reviewer, with included results checked for alignment with the protocol by 
two further reviewers. Results: The mean QOL as measured using the EuroQOL 
5-dimension questionnaire (EQ-5D) was reported to be 0.86 for PC. After diagnosis of 
PC, a 0.02 point drop in the mean EQ-5D score was reported in the first two months 
of treatment. QOL assessment tools used, however, varied considerably between 
studies impairing data synthesis and comparison. Adverse events were commonly 
associated with PC treatments and resulted in decreased patient QOL. Urinary and 
sexual function problems were of greatest importance to males undergoing treat-
ment for PC. Erectile dysfunction was commonly reported and was present in 93.9% 
of men who received prostatectomy and radiotherapy. Nearly 14% of patients were 
willing to trade survival time for increased QOL. cOnclusiOns: PC is associated 
with reduced patient QOL and a large determinant in the QOL decrement appears to 
be the PC treatment received and its associated adverse events. Patient willingness 
to trade survival and QOL has important health economic implications.
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Objectives: In the PREVAIL trial, enzalutamide improved survival and HRQOL 
in men with chemo-naïve mCRPC. This analysis provides additional in-depth 
insights into the effects of enzalutamide and placebo on EQ-5D dimensions in 
PREVAIL. MethOds: In PREVAIL, the EQ-5D self-report questionnaire and Visual 
Analogue Scale (VAS) were used to assess HRQOL and were reported up to study 
week 61. Dimensions of health states were used to generate a summary score (EQ-5D 
Index) based upon UK societal preference weights. Paretian Classification of Health 
Change (PCHC) and time to event analyses were also conducted. Results: HRQOL 
deterioration (indicated by decreases in EQ-5D Index and VAS scores) was more 
gradual with enzalutamide versus placebo; reductions were significantly (p< 0.05) 
smaller with enzalutamide in EQ-5D Index up to Week 37 and in EQ-VAS up to Week 
61 (except Week 49). Benefits of enzalutamide were primarily in the Pain/Discomfort 
dimension, with significant between-group differences (p< 0.05) through to Week 
37. PCHC analysis showed a higher percentage of enzalutamide patients reporting 
improvements on EQ-5D dimensions up to Week 49 and a higher proportion of 
placebo patients reporting worsening up to week 25. Time to event analysis showed 
superiority of enzalutamide on time to shift from full health (state 11111) and time 
to first worsening on the Pain/Discomfort and Anxiety/Depression dimensions. At 
Week 61, of patients originally randomised to enzalutamide, 20.1% reported being 
in full health (state 11111), 28.2% reported no pain or discomfort, and 43.1% reported 
no anxiety/depression compared with 5.1%, 6.5%, and 10.2%, respectively, of placebo 
patients. cOnclusiOns: In PREVAIL, as well as improving overall survival versus 
placebo, enzalutamide showed HRQOL benefits captured through EQ-5D Index and 
VAS scores, including benefits in the Pain and Discomfort dimension of EQ-5D, and 
reporting being in full health, having no pain/discomfort, or no anxiety/depression.
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trials’ data were retrieved from the Haute Autorité de Santé (HAS) website and the 
Number Needed to Treat (NNT) to prevent one event (progression, death) was esti-
mated. An Absolute Loss of Chance (ALOC) index was calculated over the time-lag 
period and per time unit combining NNT and HAS target population size. Drugs 
with level 5 Added Medical Value (ASMR, Amélioration du Service Médical Rendu) 
were excluded. Results: Twelve drugs were granted a EUMA for solid tumours in 
2012 and 2013 with level 2-4 Added Medical Value: one drug of level 2-important 
(trastuzumab emtansine), five drugs of level 3-moderate (cabazitaxel, vemurafenib, 
critzotinib, pertuzumab, and enzalutamide), and six drugs of level 4-minor (eribu-
line, ipilimumab, abiraterone, vandetanib, axitinib, and vismodegib). The time-lags 
between EUMA and FPRD ranged from 7.4 months (enzatulamide) to 29.9 months 
(cabazitaxel). Concurrently, the overall ALOC ranged from 9 to 799 medical events 
which might have not been prevented unless alternative access (Compassionate, 
Clinical Trials), depending on drug, indication and time-lag. cOnclusiOns: Early 
patient access for innovative drugs in oncology might help preventing a substantial 
number of progressions and deaths. ALOC might support patient access decision 
making process.
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Objectives: The aim of this study was to assess the burden of hospitalizations for 
metastatic renal cell carcinoma (mRCC) from 2008 to 2013 in France. MethOds: A 
retrospective analysis was performed using the French national hospital database 
(PMSI). Hospital stays for mRCC between 2008 and 2013 were identified by combining 
the International Classification of Diseases-10threvision (ICD-10) codes for renal cell 
carcinoma (C64) and codes for metastasis (C77 or C78 or C79). Among hospital stays, 
incident cases were selected and followed for at least 1 year. Descriptive analyses 
were performed with a focus on hospital stays and patient characteristics. Results: 
Overall, 26 124 adult patients (median age at diagnosis 71 years [18-102] years); 
67.8 % male) were hospitalized for mRCC, corresponding to 123 385 hospital stays 
mainly in public settings (80.1%). Among those patients, 13 517 (51.7 %) had lung 
metastasis, 10 149 (38.8%) had bone and bone marrow metastasis, 7 553 (28.9%) 
had liver metastasis and 3 538 (13.5%) had brain metastasis. The number of new 
cases per year was stable while the number of hospitalizations increased 37.4% 
from 2008 to 2013. Death in a hospital setting was reported for 4 443 (17%) patients. 
During the study period, there were 36 205 (29.3%) hospital stays for chemotherapy 
and immunotherapy, 9 400 (7.6%) hospital stays for radiotherapy and 5 956 (4.8%) 
hospital stays for palliative care. The mean length of stay at diagnosis was 10.1 (SD: 
13.9) vs. 4.4 (SD: 9.3) days for subsequent stays. cOnclusiOns: To our knowledge 
this is the first study to provide an overview of the burden of mRCC in French hos-
pitals between 2008 and 2013 and constitutes the preliminary step in assessing the 
economic burden of hospitalizations for mRCC.
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Objectives: The aim of this study was to describe the burden of metastatic mela-
noma in public and private hospitals between 2008 and 2013 in France. MethOds: 
The French national hospital database (PMSI) was analyzed to identify adults 
newly diagnosed with metastatic melanoma between 2008 and 2013. Using the 
International Classification of Diseases 10threvision codes for melanoma (C43) and 
for metastasis (C77 or C78 or C79), the number of hospital admissions for metastatic 
melanoma was identified and thereafter the corresponding number of hospitalized 
patients was determined. Descriptive analyses were performed with a focus on 
hospital stays and patient characteristics. Results: Between 2008 and 2013, 16 188 
patients (median age at diagnosis 66 years [18 -103]; 54.6 % male) were hospitalized 
for metastatic melanoma, corresponding to 104 731 hospital admissions mainly in 
public settings (94.8%). We identified 27 523 (26.3%) hospital admissions for chemo-
therapy and immunotherapy and only 2 943 (2.8%) hospital admissions for pallia-
tive care. 24.0% of diagnosis related groups were classified as surgery procedures. 
Hospital admissions were mainly performed in three regions: Ile-de-France (18.6%), 
Rhône Alpes (13.1%) and Aquitaine (12.6%). The mean length of stay was 3.2 days (SD: 
7.1). 39.8% of patients had 1 site of metastasis, 18.0% had 2 sites of metastasis and 
42.1% had at least 3 sites of metastasis. The most common sites of metastasis were 
lung in 36.8% of patients, liver in 28.8% of patients and brain in 27.8% of patients. 
Death in a hospital setting was reported for 10.3% of patients. cOnclusiOns: This 
analysis allows us to strengthen our knowledge regarding the burden of metastatic 
melanoma which represents a first step in assessing the cost of hospitalizations 
related to metastatic melanoma. Such analysis is useful for economic modeling 
especially with the arrival of innovative treatments.
PCN262
searCh fOr CliNiCally aNd eCONOmiCally effeCtive lymPhOmas 
treatmeNt
Lishchyshyna O, Rubtsova I, Shilkina O
State Expert Centre of the Ministry of Health of Ukraine, Kyiv, Ukraine
Objectives: There is an acute problem concerning lymphoma treatment in 
Ukraine. Previously, due to unavailability of up-to-date chemotherapy (CT) regimes, 
only 20% of lymphoma patients had a chance for persistent remission after the 
treatment, 40-60% of patients had response to treatment and only 35% of patients 
had 5-year survival rates. Todays clinical protocols of therapy in lymphoma patients 
take into account world’s experience. MethOds: Clinical Practice Guidelines for the 
Diagnosis and Management of Lymphoma. A National Health and Medical Research 
illomavirus vaccine acceptance in Asian populations. MethOds: Students studying 
undergraduate health professional courses (Medicine, Dentistry, Pharmacy, Nursing) 
in a private medical University in Kuala Lumpur, Malaysia in the period from June 
2014 - January 2015 were selected. The participants’ demographic details were gath-
ered by a self-administered questionnaire. The contingent valuation method was 
used to assess each respondent’s willingness to pay to take HPV vaccination and 
reduce the risk of cervical cancer. This method represents a single “take it or leave it 
offer”, whereby people are asked if they are willing to pay a specific pre-determined 
price for the benefit presented. Results: The mean age of the respondents was 23.5 
years, (SD ±1. 0). 55.2% reported as being in a relationship. Most of the participants 
were willing to pay an amount up to RM 500 to receive HPV vaccination. The median 
WTP for HPV vaccination is RM 465. Age, gender, and the patient’s perceived health 
status at baseline were not associated with WTP. Respondents who are in a relation-
ship (committed and dating) showed greater interest in vaccinating themselves and 
the relationship status emerged as unique predictors; Committed (OR= 2.20, P < 0.05) 
and dating (OR = 2.20, P< 0. 05). cOnclusiOns: Avoidance of human papillomavirus 
infection and cervical cancer may have considerable value to the undergraduate 
students of health professional courses and this data will help future validation in 
a larger population in Malaysia.
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Objectives: High cost and highly effective cancer treatment are changing the 
survivorship landscape with implications for pharma, payers and patients. High 
initial cost of care may be mitigated by lower global cost of care and significantly 
lower subsequent year cost. However, such long term value may be lost if patients 
switch coverage at general market frequency. We compared published benchmark 
coverage switch data to a breast cancer and non-cancer cohort to evaluate if patients 
with a cancer diagnosis are less likely to switch coverage. MethOds: Breast cancer 
patients and a control group of non-cancer patients were identified using data 
obtained from the Cardinal Health Specialty Solutions Revenue Cycle Management 
(RCM) medical claims database. Patients had a claim during the 12 month period 
ending April 2014, were 60 years old or younger, diagnosed as of 2011 or later, and 
had at least 3 years of follow-up data available. Payer information at index period 
and at time of switch was recorded and insurance patterns examined. Data was ana-
lyzed using a chi-square test and Kaplan-Meier graphs. Results: There were 1440 
patients with breast cancer and 3950 patients with non-cancer diagnoses in the final 
study sample. Breast cancer patients switched payer at a statistically lower propor-
tion than the non-cancer control group, 22.7% versus 26.0% respectively (p= 0.014). 
Time to payer switch estimated through a Kaplan-Meier analysis demonstrated 
a longer time to payer switch for breast cancer patients versus the control group 
(3.59 years versus 3.56 years, p= 0.037). cOnclusiOns: Despite protection against 
pre-existing condition uninsurability, a lower proportion of breast cancer patients 
switched payers during the study time window and had a longer estimated time 
to payer switch. Such trends will be of interest to payers and pharma as both seek 
understanding of value based care for their respective businesses.
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Objectives: HCV infection caused 1,2 million DALY in 2002 in Europe and 200 104 
YLDs. 1% of these YLDs resulted from HCV-related hepatocellular carcinoma. The 
objective of the present study is to calculate the DALY for patients with HCV-related 
HCC in Bulgaria. MethOds: It is a retrospective real-life observational study of 445 
patients with hepatocellular carcinoma registered in the National Cancer Registry 
for 2-year period (2012-2014). Data on demographic, clinical characteristics, previ-
ous, and concomitant diseases of the liver was collected from the patient registries. 
DALYs for these patients wàs calculated based on the WHO methodology. Results: 
350 of the observed patients were diagnosed with HCC in 3rd and 4th stage and 280 
of the patients were in productive ages. The mortality rate was significantly high – 
83% for the observed period. Chronic HCV infection and cirrhosis were found to be 
leading pathology for the development of HCC as ~ 20% of the patients with HCC 
and previous/concomitant liver diseases reported chronic hepatitis C infection and 
cirrhosis. For the 445 patients were calculated 798 years life lost (YLL) and 958 years 
lived with disability (YLD). DALY accounted for 1756. cOnclusiOns: HCV-related 
cirrhosis and HCC implicit high social burden. The high mortality rate causes huge 
productivity losses for the society.
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Objectives: Our objectives were to report time-lags between European Marketing 
Authorisation (EUMA) and French Pricing and Reimbursement Decision (FPRD) for 
recent innovative anti-cancer drugs and to quantify the corresponding patient loss 
of chance. MethOds: We included 2012-2013 EMA-approved anti-cancer drugs in 
solid tumours and calculated the time-lag between EUMA and FPRD. Official pivotal 
